09:59 AM EST - Acerus Pharmaceuticals Corporation : Has received an additional $2 million under its secured term credit facility with Quantius Inc.. This additional $2 million represented the second tranche of the $5-million Quantius Facility entered into late in 2017 and was conditional on Acerus achieving certain commercial milestones. These conditions included our U.S. Partner for NATESTO® reaching a set number of total prescriptions per month as well as Acerus, maintaining ESTRACE® sales at a set minimum level. Acerus Pharmaceuticals Corporation
shares T.ASP are trading up $0.015 at $0.35.
